Enanta Pharma (ENTA) Tops Q1 EPS by 33c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Enanta Pharma (ENTA) Tops Q1 EPS by 33c

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET

February 8, 2021 4:02 PM EST

Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021 Initiated RSVTx, a Phase 2b Study of EDP-938 in Adult Hematopoietic Cell Transplant Recipients with Acute Respiratory Syncytial Virus (RSV) Infection Expanded RSV Program with a Discovery Initiative for Novel RSV L-Protein Inhibitors Royalty Revenue for the Quarter was $31.7 Million Cash and Marketable Securities Totaled $404.7 Million at December 31, 2020

WATERTOWN, Mass.--(BUSINESS... More